Safety considerations when using non-ergot dopamine agonists to treat Parkinson’s disease

Fabrizio Stocchi, Barbara Fossati, Margherita Torti

Research output: Contribution to journalReview articlepeer-review


Introduction: Nonergot dopamine agonists (NEDA) represent an excellent treatment option for Parkinson’s disease (PD) patients, in both early and advanced stages of the disease. The post-marketing phase of NEDA has highlighted, though, the occurrence of important long-term adverse events. Areas covered: This review reports recent updates on NEDA adverse events, analyzing neurobiological bases and risk factors of these complications. A literature search has been performed using Medline and reviewing the bibliographies of selected articles. Expert opinion: NEDA represents a very important option in the treatment of PD. Criticisms on their use can be overcome through a better knowledge of these molecules and of the risk factors for adverse events which allow specialists to prevent the occurrence of undesired complications and consent a tailor-based approach. Abbreviations: PD: Parkinson’s disease, DA: dopamine agonists, NEDA: non-ergot dopamine agonists, ICD: impulse control disorders, DAWS: dopamine agonist withdrawal syndrome, CYP: Cytochrome P, PK: pharmacokinetic, AUC: area under the curve, HRT: hormone replacement therapy, AV: atrioventricular, HF: heart failure, OH: orthostatic hypotension, RBD: REM behavior disorders, PDP: Parkinson’s disease psychosis, DRT: dopamine replacement therapy, DDS: dopamine dysregulation syndrome, MMSE: Mini-Mental state examination, EDS: excessive daytime somnolence.

Original languageEnglish
Pages (from-to)1155-1172
Number of pages18
JournalExpert Opinion on Drug Safety
Issue number9
Publication statusPublished - Sep 1 2020


  • Dopamine agonists
  • heart failure
  • impulse control disorders
  • non ergot derivatives
  • parkinson’s disease
  • safety
  • safety3
  • side effects

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Safety considerations when using non-ergot dopamine agonists to treat Parkinson’s disease'. Together they form a unique fingerprint.

Cite this